

ASX ANNOUNCEMENT

6 May, 2025

Biome Launches New Brand Activated Therapeutics

- Biome set to launch new brand alongside Activated Probiotics in Q4
- Four new products, including natural medicines and formulations, with evidence-based therapeutic applications.
 - Oestro-ISO - for perimenopause symptoms
 - Synbio-GOS - for gastrointestinal repair
 - Pepti-BIOTIC - for acid reflux
 - Macro-PRO - for weight management and nutritional support, including people taking GLP-1 medications
- These new products expand Biome's reach into new health areas, enabling broader support for both health practitioners and their patients.

Microbiome health company **Biome Australia Limited** (ASX: BIO) ('Biome' or 'the company') is pleased to provide an update on the launch of a new brand: *Activated Therapeutics*.

Activated Therapeutics has been created alongside Biome's flagship probiotic brand, *Activated Probiotics*, as a complementary platform for the release of natural medicine products that meet clearly defined health needs with strong market demand. While evidence-based probiotics remain central to Biome's product development pipeline, Activated Therapeutics enables us to broaden our therapeutic offering where non-probiotic solutions are best suited to address specific needs. This allows Biome to expand its mission of preventing disease and improving health outcomes to a broader range of patients looking for natural solutions to their health needs.

Activated Therapeutics will launch into the market initially with four specialised products, each formulated with natural ingredients with specific evidence-based therapeutic applications.

The *Activated Therapeutics* range is also a reflection of our continued commitment to evidence-based, microbiome-centered innovation. *Biome* is leveraging its expertise in the health effects of the gut microbiome – gained through years of work in the probiotic industry – to drive product development in this new range, with a number of products incorporating microbiome-focused ingredients beyond probiotics, including prebiotics and postbiotics.

Activated Therapeutics will be positioned as a practitioner-only range, available to health practitioners in private practice and positioned behind-the-counter in community pharmacy, helping to deliver better patient outcomes through effective evidence-based natural medicines and functional nutritional support.

Biome has presented the range to its existing network of health practitioner distributors, pharmacy distributors and pharmacy banner groups, and is very pleased with the strong support for launching the new lines from June 2025 onward.

These products have been formulated to help meet the demands of health practitioners and patients alike, fill market gaps in the complementary medicine industry, work alongside pharmaceutical interventions and open up the potential to drive meaningful business growth.

ACTIVATED THERAPEUTICS



Oestro-ISO

Premenopause support

- A standardised soy isoflavone supplement for the relief of menopausal symptoms, including hot flushes, night sweats, irritability and mood swings.
- Positioned as natural symptom relief for the 80% of women who experience symptoms at menopause and the 25% of women who experience severe or prolonged menopausal symptoms that affect their quality of life.¹
- Women's health is the number 1 dietary supplements category by sales volume in Australia, with menopause and healthy ageing products becoming more in demand globally in recent years.²

¹ Royal Australian and New Zealand College of Obstetrics and Gynaecology. Clinical Guidance: Managing Menopausal Symptoms. 2020. <https://ranzocg.edu.au/wp-content/uploads/Managing-Menopausal-Symptoms.pdf>

² Complementary Medicines Australia. (2024). CMA Snapshot 2024. Available from <https://cmaustralia.org.au/wp-content/uploads/CMA-Snapshot-2024.pdf>

Synbio-GOS

Gastrointestinal repair

- A synergistic synbiotic to support gut healing, balance the microbiome, and restore digestive health.
- This product contains a prebiotic fibre and two probiotic strains that have been shown to 'feed' upon this fibre³, creating the potential for greater health effects than if supplementing either component on their own.

Pepti-BIOTIC

Acid reflux

- A postbiotic-rich fermented soy powder which helps to reduce the severity and frequency of heartburn over time.⁴
- Positioned as a natural, long-term solution for heartburn relief, this product also creates a significant co-prescribing opportunity alongside high-volume proton pump inhibitors which are ranked 3rd and 4th on the PBS list of top 50 PBS drugs by highest total prescription volume (2023–2024).⁵

Macro-PRO

Weight management, GLP-1 support, and nutritional support for healthy ageing

- Macro-PRO™ is a plant-based formulated meal replacement with organic wholefood ingredients and no added sugar
- Positioned as a high-quality, nutrient-dense and vegan-friendly alternative to conventional shakes for patients requiring nutritional support, including:
 - Elderly and sick patients at risk of undernutrition
 - Those pursuing weight loss programs

³ Ghyselinck, J., Teixeira, J., Marzorati, G., & Harthoorn L. (2024). A Novel Synbiotic Blend of Galactooligosaccharide (GOS) and a Two-Strain Probiotic Acts Synergistically to Increase Lactate and Short-Chain Fatty Acid Production in a Short-Term Ex Vivo Colon Fermentation Model. *International Journal of Nutritional Sciences*, 9(1).

⁴ Fatani, A., Vaher, K., Rivero-Mendoza, D., Alabasi, K., & Dahl, W. J. (2020). Fermented soy supplementation improves indicators of quality of life: A randomized, placebo-controlled, double-blind trial in adults experiencing heartburn. *BMC Research Notes*, 13(1).

⁵ Department of Health and Aged Care. (2024, December 19). PBS Expenditure and Prescriptions Report 1 July 2023 to 30 June 2024. Pharmaceutical Benefits Scheme. Available from: <https://www.pbs.gov.au/statistics/expenditure-prescriptions/2023-2024/PBS-Expenditure-prescriptions-report-2023-24.PDF>

- Patients taking GLP-1 medications who may have trouble eating due to gastrointestinal side effects
- Can be consumed as a nutrient-dense snack between meals for those with elevated nutrient requirements, or as a complete meal replacement for those who have reduced appetite, impaired ability to prepare meals, or are reducing their caloric intake.

Biome Australia's Managing Director and Founder, Blair Vega Norfolk, commented:

"I am proud to welcome Activated Therapeutics to Biome's portfolio. We have developed a strong position of trust in the microbiome health space through Activated Probiotics as well as through our efforts in educating health professionals on strain-specific probiotic science. The Activated Therapeutics platform will allow for ongoing product development beyond probiotics. Biome continues to review breakthrough research and new concepts in natural medicine. Activated Therapeutics has come at the perfect time for us to support new patient groups in need with these gut-health adjacent products."

References

1. Royal Australian and New Zealand College of Obstetrics and Gynaecology. Clinical Guidance: Managing Menopausal Symptoms. 2020. Retrieved from: <https://ranzcog.edu.au/wp-content/uploads/Managing-Menopausal-Symptoms.pdf>
2. Complementary Medicines Australia. (2024). CMA Snapshot 2024. Retrieved from: <https://cmaustralia.org.au/wp-content/uploads/CMA-Snapshot-2024.pdf>
3. Ghyselinck, J., Teixeira, J., Marzorati, J., & Harthoorn L. (2024). A Novel Synbiotic Blend of Galactooligosaccharide (GOS) and a Two-Strain Probiotic Acts Synergistically to Increase Lactate and Short-Chain Fatty Acid Production in a Short-Term Ex Vivo Colon Fermentation Model. *International Journal of Nutritional Sciences*, 9(1).
4. Fatani, A., Vaher, K., Rivero-Mendoza, D., Alabasi, K., & Dahl, W. J. (2020). Fermented soy supplementation improves indicators of quality of life: A randomized, placebo-controlled, double-blind trial in adults experiencing heartburn. *BMC Research Notes*, 13(1).
5. Department of Health and Aged Care. (2024, December 19). PBS Expenditure and Prescriptions Report 1 July 2023 to 30 June 2024. Pharmaceutical Benefits Scheme. Retrieved from: <https://www.pbs.gov.au/statistics/expenditure-prescriptions/2023-2024/PBS-Expenditure-prescriptions-report-2023-24.pdf>

–ENDS–

Approved for release by the Biome Australia board of directors.

Investor Hub

Biome has launched a new interactive investor hub. To view a video presentation of this announcement, ask questions or sign up for future company updates, please visit the investor hub via [this link](https://investorhub.biomeaustralia.com/) (<https://investorhub.biomeaustralia.com/>).

About Biome Australia Limited

Biome Australia develops, licenses, commercialises and markets innovative, evidence-based live biotherapeutics (probiotics) and complementary medicines, many of which are supported by clinical research. Biome aims to improve health outcomes and quality of life, and make its products accessible to all.

Incorporated in Australia in 2018, Biome distributes locally and abroad. In partnership with some of the world's leading organisations in microbiome research and development, Biome produced several unique live biotherapeutic (probiotic) products with innovative delivery technologies that improve their stability and efficacy to create its flagship range of complementary medicines: Activated Probiotics[®].

Supported by clinical research, including randomised double-blind placebo-controlled trials, Activated Probiotics help prevent and support the management of various health concerns, including low mood and sleep, bone health, iron malabsorption, mild eczema and IBS. Through practitioner-only distribution, Biome is committed to educating health professionals on the newfound systemic health effects of the gut microbiota, helping them to provide innovative, evidence-based natural medicines for the management of some of humanity's most prevalent and chronic health concerns.

Biome also develops, licenses and distributes a scientifically formulated, organic nutraceutical range, Activated Nutrients[®].

For more information visit: www.biomeaustralia.com

Investor Relations

Rechelle Friend
corporate@biomeaustralia.com
(03) 9017 5800

Forward looking statements

*This release may contain forward looking statements, including but not limited to projections, guidance on future revenues, earnings, other potential synergies and estimates and the future performance of Biome (**Forward Looking Statements**).*

Forward Looking Statements are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. Actual results, performance or achievements may differ materially from those expressed or implied in such Forward Looking Statements and any projections and assumptions on which these Forward Looking Statements are based. Such statements may assume the success of Biome's business strategies. You are cautioned not to place undue reliance on Forward Looking Statements.

The Forward Looking Statements are based on information available to Biome as at the date of this release. Any Forward Looking Statements containing forward looking financial information provided in this release is for illustrative purposes only and is not represented as being indicative of Biome's views on its future financial condition and/or performance.

Nothing in this release is a promise or representation as to the future. No representation or warranty, express or implied, is made as to the accuracy, likelihood of achievement or reasonableness of any Forward Looking Statements contained in this release. Except as required by law or regulation (including the ASX Listing Rules), Biome does not undertake to provide any additional or updated information whether as a result of a change in expectations or assumptions, new information, future events or results or otherwise.

To the maximum extent permitted by law, Biome excludes and expressly disclaims all liabilities in respect of, and makes no representation or warranty, express or implied as to the fairness, currency, accuracy, reliability or completeness of information in this release or the accuracy, likelihood of achievement or reasonableness of any Forward Looking Statements (or any event or results expressed or implied in any Forward Looking Statements) contained in, implied by, the information in this release or any part of it, or that this release contains all material information about Biome or which a prospective investor or purchaser may require in evaluating a possible investment in Biome or acquisition of securities in Biome.

Investors are strongly cautioned not to place undue reliance on Forward Looking Statements, particularly in light of the current economic climate and the significant volatility, uncertainty and disruption caused by the Covid-19 pandemic.
